Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Fresenius
Thumbnail
March 11, 2022

Alvotech settlement completes the list of Humira challengers

Thumbnail
June 02, 2021

US FDA approval tracker: May

Article image
Vantage logo
April 30, 2021

Go or no go? Apellis and Heron head for the finish line

May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.

Article image
Vantage logo
January 21, 2021

Biopharma’s stock market winners and losers in 2020

Article image
Vantage logo
March 11, 2020

Tiziana takes a deep breath and targets Covid-19

Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?

Article image
Vantage logo
November 07, 2018

Abbvie manoeuvres to defend Humira to the last

Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.

Vantage logo
June 15, 2018

Snippet roundup: Panel says no to BTG and Sirtex says no to Varian

Article image
Vantage logo
June 05, 2018

Forecasts tell a tale of two continents for biosimilars

Despite government rhetoric, the US biosimilar market has failed to live up to expectations so far.

Vantage logo
April 23, 2018

Akorn falls as Fresenius backs away

Vantage logo
April 17, 2018

Private equity cleans up Sanofi’s failed generics foray

Vantage logo
March 02, 2018

Snippet roundup: Mylan lines up Botox biosimilar but Vernalis sinks

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.